Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 3,850,000 shares, a decrease of 27.1% from the October 31st total of 5,280,000 shares. Based on an average daily trading volume, of 3,160,000 shares, the days-to-cover ratio is currently 1.2 days.
Analysts Set New Price Targets
A number of research analysts have recently commented on CAPR shares. Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an "overweight" rating and a $35.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday, November 14th. Maxim Group raised their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Cantor Fitzgerald upped their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, November 14th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $34.50.
Read Our Latest Report on Capricor Therapeutics
Insiders Place Their Bets
In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm's stock in a transaction that occurred on Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.00% of the company's stock.
Institutional Investors Weigh In On Capricor Therapeutics
Large investors have recently modified their holdings of the stock. Main Street Financial Solutions LLC boosted its stake in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock valued at $131,000 after buying an additional 7,500 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at $133,000. Bank of New York Mellon Corp grew its holdings in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after purchasing an additional 9,040 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth about $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new stake in shares of Capricor Therapeutics during the 3rd quarter worth about $192,000. 21.68% of the stock is currently owned by institutional investors.
Capricor Therapeutics Trading Down 0.2 %
NASDAQ CAPR traded down $0.03 on Friday, reaching $19.01. The company's stock had a trading volume of 571,850 shares, compared to its average volume of 1,148,096. Capricor Therapeutics has a 52 week low of $2.90 and a 52 week high of $23.40. The firm has a market cap of $864.38 million, a PE ratio of -17.93 and a beta of 4.00. The business has a 50-day moving average price of $18.03 and a 200 day moving average price of $9.38.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
